Olema Pharmaceuticals, Inc. — Investor Relations & Filings
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers. The company concentrates on endocrine-driven diseases, with a primary emphasis on breast cancer. Its lead product candidate, palazestrant (OP-1250), is an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). Palazestrant is under investigation in clinical trials as a potential treatment for patients with ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is advancing a pipeline of drug candidates with the goal of developing improved therapeutic options for cancer patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-26 | English | |
| 8-K | 2026-05-21 | English | |
| 10-Q - Olema Pharmaceuticals, Inc. (0001750284) (Filer) | 2026-05-12 | English | |
| 8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer) | 2026-05-12 | English | |
| 8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer) | 2026-05-01 | English | |
| SCHEDULE 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject) | 2026-03-20 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47060269 | 8-K | 2026-05-26 | English | ||
| 46753709 | 8-K | 2026-05-21 | English | ||
| 45235873 | 10-Q - Olema Pharmaceuticals, Inc. (0001750284) (Filer) | 2026-05-12 | English | ||
| 45234135 | 8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer) | 2026-05-12 | English | ||
| 39647982 | 8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer) | 2026-05-01 | English | ||
| 32999839 | SCHEDULE 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject) | 2026-03-20 | English | ||
| 31582743 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31582732 | 4 Filing | 2026-02-17 | English | ||
| 31582675 | 3 Filing | 2026-02-17 | English | ||
| 31582686 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 31582850 | SCHEDULE 13G Filing | 2026-02-05 | English | ||
| 31582849 | 4 Filing | 2026-02-04 | English | ||
| 31582785 | 4 Filing | 2026-02-04 | English | ||
| 31582739 | 4 Filing | 2026-02-04 | English | ||
| 31582729 | 4 Filing | 2026-02-04 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Olema Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32591/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32591 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32591 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32591 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32591}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Olema Pharmaceuticals, Inc. (id: 32591)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.